Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M9,177Revenue $M355Net Margin (%)-23.4Z-Score3.2
Enterprise Value $M9,341EPS $-0.6Operating Margin %-4.5F-Score2
P/E(ttm))0Cash Flow Per Share $-1.3Pre-tax Margin (%)-23.3Higher ROA y-yN
Price/Book010-y EBITDA Growth Rate %0Quick Ratio5.1Cash flow > EarningsY
Price/Sales23.75-y EBITDA Growth Rate %0Current Ratio5.1Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %-192.7ROA % (ttm)-13.2Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)0Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M168ROI % (ttm)-131.6Gross Margin Increase y-yN

Gurus Latest Trades with INCY

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
INCYVanguard Health Care Fund 2014-06-30 Add0.68%$43.1 - $56.39
($50.98)
$ 53.946%Add 95.66%9,591,143
INCYMariko Gordon 2014-06-30 Reduce-0.19%$43.1 - $56.39
($50.98)
$ 53.946%Reduce -78.93%23,728
INCYGeorge Soros 2014-06-30 Sold Out -0.01%$43.1 - $56.39
($50.98)
$ 53.946%Sold Out0
INCYGeorge Soros 2014-03-31 Buy 0.01%$49.94 - $68.83
($61.83)
$ 53.94-13%New holding, 23200 sh.23,200
INCYMariko Gordon 2013-12-31 Reduce-0.06%$34.71 - $51.34
($43.45)
$ 53.9424%Reduce -20.5%128,959
INCYVanguard Health Care Fund 2013-06-30 Add0.05%$19.07 - $24.49
($21.85)
$ 53.94147%Add 21.52%3,807,443
INCYVanguard Health Care Fund 2013-03-31 Buy 0.29%$16.61 - $24.95
($20.44)
$ 53.94164%New holding, 3133100 sh.3,133,100
INCYGeorge Soros 2011-03-31 Sold Out $13.37 - $16.56
($14.71)
$ 53.94267%Sold Out0
INCYGeorge Soros 2010-12-31 Buy $14.51 - $17.17
($16.13)
$ 53.94234%New holding, 15000 sh.15,000
INCYJean-Marie Eveillard 2009-03-31 Sold Out $2.14 - $3.78
($2.9)
$ 53.941760%Sold Out0
INCYJean-Marie Eveillard 2008-12-31 Buy $2.82 - $4.89
($3.8)
$ 53.941320%New holding, 11300 sh.11,300
INCYGeorge Soros 2008-09-30 Sold Out -0.02%$7.31 - $10.23
($9.2)
$ 53.94486%Sold Out0
INCYGeorge Soros 2008-06-30 Add0.01%$7.6 - $11.27
($9.8)
$ 53.94450%Add 52.29%74,558
INCYGeorge Soros 2008-03-31 Reduce-0.01%$9.27 - $12.36
($10.6)
$ 53.94409%Reduce -57.34%48,958
INCYGeorge Soros 2007-12-31 Reduce-0.03%$7.85 - $10.59
($8.9)
$ 53.94506%Reduce -45.42%114,758
INCYJean-Marie Eveillard 2007-09-30 Sold Out $4.81 - $7.15
($5.9)
$ 53.94814%Sold Out0
INCYJean-Marie Eveillard 2007-06-30 Reduce$6.2 - $7.9
($7.1)
$ 53.94660%Reduce -78.26%50,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

INCY is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
INCY Vanguard Health Care Fund 2014-06-309,591,1435.721.4+95.66%
INCY Mariko Gordon 2014-06-3023,7280.010.06-78.93%
INCY George Soros 2014-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


INCY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Daly James MEVP, Chief Commercial Officer 2014-08-25Sell11,111$51.964.41view
Levy Richard SEVP, Chief Drug Dev&Medical Of 2014-08-18Sell8,000$51.974.39view
Daly James MEVP, Chief Commercial Officer 2014-07-23Sell11,111$48.5411.76view
Levy Richard SEVP, Chief Drug Dev&Medical Of 2014-07-16Sell8,000$48.1512.67view
Daly James MEVP, Chief Commercial Officer 2014-06-23Sell11,111$56.03-3.18view
Levy Richard SEVP, Chief Drug Dev&Medical Of 2014-06-16Sell8,000$53.880.69view
HASTINGS DAVID CCFO 2014-06-05Sell200,000$52.732.88view
Daly James MEVP, Chief Commercial Officer 2014-05-23Sell11,111$48.4811.9view
Levy Richard SEVP, Chief Drug Dev&Medical Of 2014-05-16Sell8,000$50.687.04view
Chardonnet LaurentVice President and Treasurer 2014-05-12Sell2,058$540.46view

Press Releases about INCY :

    Quarterly/Annual Reports about INCY:

    News about INCY:

    Articles On GuruFocus.com
    Weekly CFO Sells Highlight: Aramark, Incyte Corp Ltd., Facebook Inc. Jun 09 2014 
    Weekly Insider Sells Highlight: ARMK, INCY, ESC, HUN Jun 08 2014 
    Weekly Insider Sells Highlight: CPN, INCY, GPK, CODE Feb 23 2014 
    Weekly CFO Sells Highlight: Pandora Media Inc, Incyte Corp Ltd, Google Inc, American Airlines Group Feb 24 2014 
    Weekly CEO Sells Highlight: ExOne Co, Atmel Corporation, Best Buy and Incyte Corp Ltd. Sep 22 2013 
    Weekly CFO Sells Highlight: INTU, INCY, RLD, MIDD, XONE Sep 15 2013 
    Weekly CEO Sells Highlight: DIS, LMT, INCY, ADBE May 14 2012 
    Weekly Top Insider Buys: VTR, INCY, FULT, HMA, CMC Jan 23 2012 
    04 stocks with insider buying of more than $1.5 million since beginning of 2012 Jan 22 2012 
    Weekly CFO Sales Highlight: EPIQ, INCY, AVB, JOSB, PCS, FLO Jun 12 2011 


    More From Other Websites
    Earnings Estimates Moving Higher for Incyte Corporation (INCY): Time to Buy? Aug 27 2014
    INCYTE CORP Financials Aug 08 2014
    Scott Drake, CEO, and Guy A. Childs, CFO of The Spectranetics Corporation (SPNC), Interview with The... Aug 08 2014
    FDA Accepts Supplemental New Drug Application for Jakafi® (ruxolitinib) and Priority Review Granted Aug 05 2014
    Incyte Posts Wider-than-Expected Q2 Loss, Raises Sales View Aug 01 2014
    Incyte Corp Earnings Call scheduled for 8:30 am ET today Jul 31 2014
    INCYTE CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Jul 31 2014
    Q2 2014 Incyte Corporation Earnings Release - 07:00 am ET Jul 31 2014
    Incyte Reports 2014 Second-Quarter Financial Results and Updates Shareholders on Key Clinical... Jul 31 2014
    Incyte Announces Clinical Trial Agreement to Evaluate Combination of Two Novel Cancer... Jul 30 2014
    Why Incyte (INCY) Might Surprise This Earnings Season Jul 30 2014
    Jakafi® (ruxolitinib) Product Label Expanded to Include Overall Survival Data and Additional Safety... Jul 28 2014
    Incyte's Jakafi Fails to Provide RELIEF in Polycythemia Vera Jul 24 2014
    Incyte Announces Top-Line Results from RELIEF Trial of Ruxolitinib in Patients with Polycythemia... Jul 23 2014
    Top Biotechnology Stocks Jul 23 2014
    AstraZeneca widens cancer immunotherapy net with Advaxis trial Jul 22 2014
    Incyte (INCY) Enters Oversold Territory Jul 16 2014
    Incyte to Report Second Quarter 2014 Financial Results on July 31 Jul 14 2014
    Incyte Earns Milestone Payment on Japanese Approval of Jakavi Jul 09 2014
    Incyte Achieves $25 Million Milestone for Approval of Jakavi® (ruxolitinib) in Japan Jul 08 2014

    Add Notes, Comments or Ask Questions

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK